MainboardGMP
LIVE
LIVE GMP
MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·
Home › IPOs › Alkem Laboratories Ltd.
AL
Alkem Laboratories Ltd.
CLOSED NSE & BSE Bookbuilding IPO Offer For Sale Alkem Laboratories IPO GMP
GREY MARKET PREMIUM
₹ 0
No premium data
EST. LISTING PRICE
₹1,050
Issue Price: ₹ 1,050
Issue Price
₹1,050
Face Value
₹2
Lot Size
14 shares
Open Date
08 Dec 2015
Close Date
10 Dec 2015
Listing Date
23 Dec 2015
Exchange
NSE & BSE
Alkem Laboratories IPO About the Company

Incorporated in 1973, Alkem Labs is leading India based pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.

Alkem Labs produces branded generics, generic drugs, active pharmaceutical ingredients and neutraceuticals, which they market in India and 55 countries internationally, primarily the United States.

Company's pharmaceutical business is organized into domestic and international operations. Alkem Labs has a portfolio of over 736 brands in India. Company's most significant therapeutic areas in domestic market are anti-infectives, gastro-intestinal, pain and analgesics, and vitamins, minerals and nutrients.

Alkem Labs have a total of 16 manufacturing facilities: 14 manufacturing facilities at five locations in India and two in the United States. Company have four research and development facilities, two in India and two in the United States. As of June 30, 2015, company employed 483 scientists in research and development functions.

Highlights:

1. Alkem Labs is 5th largest pharmaceutical company in India in terms of domestic sales.

2. Alkem Labs products are also sold in 56 countries. In the United States, company has filed 66 abbreviated new drug applications.

3. Company sells a range of high-quality, cost effective generic drugs to major drug chains, pharmaceutical retailers, wholesalers, food and grocery stores, distributors and managed care companies in the United States.

...read more
Alkem Laboratories IPO Objects of the Issue
Purpose Amount (₹ Cr)
1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and —
2. For the sale of 12,853,442 Equity Shares by the Selling Shareholders. —
Alkem Laboratories IPO Lead Managers
Axis Capital Ltd. Edelweiss Financial Services Ltd. JP Morgan India Pvt.Ltd. Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Financial Summary Amount in ₹ Crore
Metric 31 Mar 15 31 Mar 14 31 Mar 13
Revenue 3,360 2,840 2,469
PAT 437 440 467
Alkem Laboratories IPO Key Financial Ratios
RONW
15
Issue Details
Total Shares Offered
12,853,442 (100%)
Pre-Issue Shareholding
119,565,000 shares
Post-Issue Shareholding
119,565,000 shares
UPI Mandate
10 Dec 2015
IPO Analytics Dashboard
LIVE
Alkem Laboratories IPO GMP Insights
👤
Retail Demand
Good
💼
HNI Interest
Good
🏦
QIB Demand
Strong
📊
Valuation
Moderate
Alkem Laboratories IPO GMP Strength Score
7 / 10 Good
0–3 Weak 3–6 Moderate 6–8 Good 8–10 Strong
Alkem Laboratories IPO Category-wise Subscription Shares offered, bid & amount
Category Sub (x) Offered Bid For
🏦 QIB — 6,277,264 (49%) —
💼 NII / HNI — 1,883,179 (15%) —
👤 Retail (RII) — 4,394,086 (34%) —
🧑‍💼 Employee — 298,913 (2%) —
Σ Total — 12,853,442 (100%) —

* Amount calculated at upper price band (₹1,050) ·  ** Total includes all investor categories

Subscription Overview Share allocation by investor category
🏦
QIB ? 6,277,264 (49%)
49%
💼
NII / HNI ? 1,883,179 (15%)
15%
👤
Retail (RII) ? 4,394,086 (34%)
34%
🧑‍💼
Employee ? 298,913 (2%)
2%
Total Shares Offered 12,853,442 (100%)
Alkem Laboratories IPO Application Sizing Minimum investment by category
👤 Retail Investors ?
Min. Lots 1
Shares / Lot 14
Min. Investment ₹14,700
💼 HNI Investors ?
Min. Lots 14
Min. Shares 196
Min. Investment ₹205,800
🏛️ bHNI (>₹10L) ?
Min. Lots 69
Min. Shares 196
Min. Investment ₹1,014,300
Investor Interpretation
  • Retail allocation is good at 34% of the total offering.
  • HNI/NII demand is good at 15%.
  • Institutional (QIB) interest is strong at 49%.

This IPO shows moderate investor interest. Review financial details and compare valuation with industry peers before investing.

STOCK PRICE HISTORY  ·  NSE
—
Issue Price: ₹ 1,050  ·  Symbol: —
H —
L —
O —
Alkem Laboratories IPO Company Info
📍 Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai 400 013 Mumbai, Maharashtra
Visit Website
Alkem Laboratories IPO Registrar
MUFG Intime India Pvt.Ltd.
Check Allotment Status
Alkem Laboratories IPO FAQs
Alkem Laboratories IPO has already listed. Its last recorded GMP was ₹0. GMP is only indicative and never a guarantee of listing gains.
The issue price of Alkem Laboratories IPO is ₹1,050 per share. One lot has 14 shares, so the minimum investment is about ₹14,700. It is a Offer For Sale issue.
Alkem Laboratories IPO opened on 08 Dec 2015 and closed on 10 Dec 2015. Shares are listed on NSE & BSE on 23 Dec 2015.
Incorporated in 1973, Alkem Labs is leading India based pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.
As per the offer document, Alkem Laboratories plans to use the IPO proceeds for: 1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and; 2. For the sale of 12,853,442 Equity Shares by the Selling Shareholders..
The lead managers of Alkem Laboratories IPO are Axis Capital Ltd., Edelweiss Financial Services Ltd., JP Morgan India Pvt.Ltd., Nomura Financial Advisory & Securities (India) Pvt.Ltd..
Alkem Laboratories IPO is proposed to list on NSE & BSE; it is a Bookbuilding IPO and the issue is a Offer For Sale.
Disclaimer

The information on mainboardgmp.com is provided for educational and informational purposes only.

We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.

GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.

Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.

By using this website, you acknowledge and agree that you use the content at your own risk.